Endocrine Pharmacology Practice Questions

Q: Norgestimate in OC pills has the following advantage?

Reduces acne and hirsutism. ***reduces acne and hirsutism*** - **Norgestimate** is a third-generation progestin known for its **low androgenic activity**, which helps to counteract the androgenic effects that can contribute to acne and hirsutism when combined with estrogen. - By minimizing androgenic side effects, norgestimate-containing oral contraceptive pills (OCPs) can improve skin conditions such as **acne** and unwanted hair growth (**hirsutism**), making them a preferred choice for patients with these concerns. *May reduce the risk of venous thrombosis* - While some progestins are associated with varying risks of venous thrombosis, norgestimate does not inherently **reduce** this risk compared to other progestins; in fact, all combined OCPs carry some increased risk. - The risk of **venous thromboembolism (VTE)** is primarily influenced by the estrogen component and the specific type and dose of progestin, but norgestimate is not specifically noted for reducing this risk. *Is generally more affordable than standard OC pills* - The cost of OCPs can vary widely based on brand, generic availability, and insurance coverage; norgestimate-containing pills are not inherently more affordable than other standard OCPs. - In some cases, newer formulations or brand-name versions of norgestimate-containing pills may even be **more expensive** than older, generic alternatives. *May have cardiovascular benefits* - Combined oral contraceptives, including those with norgestimate, generally do not offer **cardiovascular benefits** and may even increase the risk of cardiovascular events, particularly in women with pre-existing risk factors. - Long-term use of OCPs, especially in smokers or those with hypertension, can elevate the risk of conditions like **myocardial infarction** and **stroke**, rather than providing benefits.

Q: Which of the following are medical management options for hyperparathyroidism?

All of the options. ***All of the options*** - **Bisphosphonates**, **calcitonin**, and **plicamycin** (mithramycin) are all therapeutic options used in the medical management of hyperparathyroidism, particularly for reducing hypercalcemia. - These agents work through different mechanisms to lower serum calcium levels, which is a primary goal in managing significant hyperparathyroidism. *Bisphosphonates* - **Bisphosphonates** inhibit osteoclast activity, thereby reducing **bone resorption** and subsequently lowering serum calcium levels. - They are particularly useful for long-term management of hypercalcemia associated with hyperparathyroidism. *Calcitonin* - **Calcitonin** directly inhibits osteoclast activity and increases renal calcium excretion, leading to a relatively rapid, but often short-lived, decrease in serum calcium. - It is often used for the **acute management** of severe hypercalcemia due to its quick onset of action. *Plicamycin* - **Plicamycin** (also known as mithramycin) is an antineoplastic antibiotic that inhibits RNA synthesis and has been shown to reduce serum calcium by inhibiting osteoclast-mediated bone resorption. - Due to its potential for significant side effects, including **renal**, **hepatic**, and **hematologic toxicity**, its use is generally reserved for severe, refractory hypercalcemia.

Q: Which of the following drugs is known to reduce the risk of both macrovascular and microvascular complications of diabetes mellitus?

Metformin. ***Metformin*** - **Metformin** is the first-line drug for type 2 diabetes with established evidence from the **UKPDS (UK Prospective Diabetes Study)** demonstrating reduction in both **macrovascular** (cardiovascular events, myocardial infarction) and **microvascular** (retinopathy, nephropathy, neuropathy) complications [1] - Particularly effective in **overweight and obese patients**, reducing diabetes-related mortality and all-cause mortality [1] - Mechanisms include decreasing **hepatic glucose production** [3], reducing intestinal glucose absorption, and improving **insulin sensitivity** [1] - Remains the **gold standard** first-line therapy per ADA/EASD guidelines *Acarbose* - Alpha-glucosidase inhibitor that delays carbohydrate absorption in the gut, reducing postprandial glucose excursions [2] - Provides glycemic control but **lacks robust evidence** for significant reduction in both macrovascular and microvascular complications - Primary benefit is in postprandial glucose management, not long-term complication prevention *Repaglinide* - Meglitinide analog that stimulates rapid, short-acting insulin release from pancreatic beta cells [1] - Effective for **postprandial hyperglycemia control** but lacks definitive large-scale trial evidence showing reduction in both macrovascular and microvascular outcomes - No cardiovascular outcome trials demonstrating complication reduction comparable to metformin *Sitagliptin* - DPP-4 inhibitor that enhances incretin hormone activity to improve glycemic control - **TECOS trial** showed cardiovascular safety (non-inferiority) but **not superiority** in reducing macrovascular or microvascular complications - Benefits include weight neutrality and low hypoglycemia risk, but less direct evidence for widespread complication reduction compared to metformin

Q: What is the mechanism of action of Voglibose?

Alpha-glucosidase inhibitor. ***Alpha-glucosidase inhibitor*** - Voglibose acts by **inhibiting alpha-glucosidase enzymes** in the small intestine (maltase, sucrase, glucoamylase), which are responsible for breaking down complex carbohydrates into absorbable monosaccharides. - This delaying effect on carbohydrate digestion and absorption leads to a **reduction in postprandial glucose levels**, making it useful for managing type 2 diabetes. - The **alpha-specificity** is clinically important as it distinguishes this drug class from other enzyme inhibitors. *Beta-galactosidase inhibitor* - **Beta-galactosidase** is involved in the breakdown of lactose into glucose and galactose. - Inhibiting this enzyme would primarily affect **lactose digestion**, which is not the mechanism of Voglibose. - This is a completely different enzyme system unrelated to diabetes management. *Lactase inhibitor* - **Lactase** is a specific type of beta-galactosidase that breaks down lactose in the intestine. - Lactase inhibition would cause lactose intolerance symptoms, not affect glucose metabolism. - This does not describe the **carbohydrate-digesting enzyme inhibition** characteristic of Voglibose. *Glucosidase inhibitor* - While **technically accurate** (Voglibose does inhibit glucosidases), this term is **too general and non-specific** for pharmacological precision. - There are multiple types of glucosidases (alpha and beta) with different substrates and functions. - In pharmacology, specifying **alpha-glucosidase** is essential because it identifies the **exact enzyme target** and mechanism, which is critical for understanding drug action, side effects, and clinical use. - The best answer requires the most precise and clinically relevant terminology.

Q: Which of the following drug classes is INCORRECTLY matched with its mechanism of action?

Biguanides - AMPK activation. ***Biguanides - AMPK activation*** - This statement describes an **INCORRECT** mechanism. - While metformin does have effects on cellular metabolism, its primary mechanism is **inhibition of mitochondrial complex I**, leading to decreased hepatic gluconeogenesis. - AMPK activation is a **downstream effect**, not the primary mechanism of action. - This is the incorrectly matched pair. *Alpha-glucosidase inhibitors - Delay carbohydrate absorption* - This statement describes the **correct** mechanism of action for alpha-glucosidase inhibitors. - They work by inhibiting enzymes (alpha-glucosidases) in the small intestine that break down complex carbohydrates into absorbable monosaccharides, thus **delaying glucose absorption**. *Sulfonylureas - Block ATP-sensitive K+ channels* - This statement describes the **correct** mechanism of action for sulfonylureas. - Sulfonylureas bind to and **close ATP-sensitive potassium channels** on pancreatic beta cells, leading to depolarization and increased insulin release. *DPP-4 inhibitors - Inhibit incretin degradation* - This statement describes the **correct** mechanism of action for DPP-4 inhibitors. - They work by inhibiting the enzyme **dipeptidyl peptidase-4 (DPP-4)**, which is responsible for the rapid degradation of **incretin hormones** like GLP-1 and GIP.

Q: What is the mechanism of action of sulfonylureas?

K ATP channel blocker. ***K ATP channel blocker*** - Sulfonylureas bind to the **sulfonylurea receptor 1 (SUR1)** subunit of the **ATP-dependent potassium (KATP) channel** on pancreatic beta cells. - This binding leads to the closure of the KATP channels, causing **depolarization of the beta cell membrane** and subsequent **insulin release**. *Sodium channel blocker* - **Sodium channel blockers** are primarily used in conditions like **cardiac arrhythmias** and **epilepsy**, by stabilizing neuron membranes or altering cardiac action potentials. - They do not directly influence **insulin secretion** from pancreatic beta cells. *Calcium channel blocker* - **Calcium channel blockers** primarily inhibit the influx of calcium ions into cells, affecting **vascular smooth muscle** and **cardiac muscle**, which can influence blood pressure and heart rate. - While calcium influx is crucial for insulin release, sulfonylureas do not directly target these channels. *Chloride channel blocker* - **Chloride channel blockers** are not a primary mechanism of action for antidiabetic medications like sulfonylureas. - Their physiological roles are diverse, including involvement in **epithelial transport** and **cellular excitability**.

Q: Which of the following antithyroid medications had the maximum chances of causing agranulocytosis?

Carbimazole. ***Carbimazole*** - **Carbimazole** has the **highest reported incidence of agranulocytosis** among antithyroid drugs (approximately **0.3-0.5%**) - Although a prodrug of methimazole, **carbimazole itself** appears to confer additional risk beyond its active metabolite - **Agranulocytosis** typically occurs within the **first 2-3 months** of therapy and requires immediate discontinuation - Patients should be counseled to report **sore throat, fever, or mouth ulcers** immediately *Methimazole* - Has a **lower incidence** of agranulocytosis compared to carbimazole (approximately **0.1-0.3%**) - Once carbimazole is metabolized to methimazole, the risk profile changes - Still requires monitoring for this serious adverse effect *Propylthiouracil* - Has **comparable or slightly higher** agranulocytosis risk than methimazole but **lower than carbimazole** - More commonly associated with **hepatotoxicity** (including fulminant hepatic failure) - Preferred in **first trimester of pregnancy** and **thyroid storm** despite its risks *Iodide* - Works by **Wolff-Chaikoff effect** (inhibits thyroid hormone synthesis and release) - Does **not cause agranulocytosis** - Main adverse effects include **iodism**, hypothyroidism, and **Jod-Basedow phenomenon** (iodine-induced hyperthyroidism)

Q: Tibolone is a ?

Synthetic steroid hormone. ***Synthetic steroid hormone*** - **Tibolone** is a **synthetic steroid** with **estrogenic, progestogenic, and weak androgenic properties** used for hormone therapy in postmenopausal women. - Its structure is derived from **nortestosterone**, making it a synthetic compound rather than naturally occurring. *Natural steroidal hormone* - Natural steroidal hormones like **estrogen** and **progesterone** are produced endogenously by the body and have specific steroidal molecular structures. - Tibolone is not a naturally occurring hormone but is manufactured in a lab. *Natural non-steroidal hormone* - Natural non-steroidal hormones typically include peptides (e.g., insulin) or amines (e.g., thyroid hormones). - Tibolone's chemical structure is clearly steroidal, not non-steroidal. *Synthetic non-steroidal hormone* - Synthetic non-steroidal hormones are compounds like **diethylstilbestrol** (DES) that mimic hormone action but lack the steroid nucleus. - Tibolone possesses a distinct steroid backbone, classifying it as a synthetic steroid.

Q: Mechanism of action of Teriparatide?

Stimulates osteoblast activity and increases bone formation. ***Stimulates osteoblast activity and increases bone formation*** - **Teriparatide** is a recombinant form of **parathyroid hormone (PTH)**. When administered intermittently, it primarily **stimulates osteoblasts** to form new bone, leading to increased bone density and strength. - This anabolic effect makes it effective in treating **osteoporosis** by promoting bone formation rather than just inhibiting bone breakdown. *Regulates glucose metabolism and insulin sensitivity* - This mechanism describes the action of drugs such as **metformin** or **GLP-1 agonists**, which are used in the treatment of **diabetes mellitus**. - **Teriparatide** is not involved in glucose regulation or insulin sensitivity. *Stimulates lactation and affects reproductive hormones* - This mechanism is characteristic of hormones like **prolactin** or drugs that modulate **gonadotropin-releasing hormone (GnRH)**, which are involved in reproductive health. - **Teriparatide's** primary role is bone metabolism, not lactation or reproductive hormone modulation. *Inhibits osteoclast activity and decreases bone resorption* - This mechanism describes the action of **bisphosphonates** or **calcitonin**, which are anti-resorptive agents used to treat osteoporosis by reducing the breakdown of bone. - **Teriparatide**, in contrast, has an overall **anabolic effect** on bone by stimulating bone formation, even though continuous PTH elevation can cause osteoclast activity.

Question 1

Norgestimate in OC pills has the following advantage?

Accepted Answer

Reduces acne and hirsutism

Answer

May reduce the risk of venous thrombosis

Answer

Is generally more affordable than standard OC pills

Answer

May have cardiovascular benefits

Question 2

Which of the following are medical management options for hyperparathyroidism?

Accepted Answer

All of the options

Answer

Bisphosphonates

Answer

Calcitonin

Answer

Plicamycin

Question 3

Which of the following drugs is known to reduce the risk of both macrovascular and microvascular complications of diabetes mellitus?

Accepted Answer

Metformin

Answer

Acarbose

Answer

Repaglinide

Answer

Sitagliptin

Question 4

What is the mechanism of action of Voglibose?

Accepted Answer

Alpha-glucosidase inhibitor

Answer

Beta-galactosidase inhibitor

Answer

Lactase inhibitor

Answer

Glucosidase inhibitor

Question 5

Anti-inflammatory actions of corticosteroids are mediated by?

Accepted Answer

By inhibiting the production of inflammatory mediators derived from phospholipids

Answer

By inhibiting angiogenesis and reducing inflammation

Answer

By promoting vascular stability

Answer

By enhancing tissue repair mechanisms

Question 6

Which of the following drug classes is INCORRECTLY matched with its mechanism of action?

Accepted Answer

Biguanides - AMPK activation

Answer

Alpha-glucosidase inhibitors - Delay carbohydrate absorption

Answer

Sulfonylureas - Block ATP-sensitive K+ channels

Answer

DPP-4 inhibitors - Inhibit incretin degradation

Question 7

What is the mechanism of action of sulfonylureas?

Accepted Answer

K ATP channel blocker

Answer

Sodium channel blocker

Answer

Calcium channel blocker

Answer

Chloride channel blocker

Question 8

Which of the following antithyroid medications had the maximum chances of causing agranulocytosis?

Accepted Answer

Carbimazole

Answer

Iodide

Answer

Propylthiouracil

Answer

Methimazole

Question 9

Tibolone is a ?

Accepted Answer

Synthetic steroid hormone

Answer

Natural steroidal hormone

Answer

Natural non-steroidal hormone

Answer

Synthetic non-steroidal hormone

Question 10

Mechanism of action of Teriparatide?

Accepted Answer

Stimulates osteoblast activity and increases bone formation

Answer

Stimulates lactation and affects reproductive hormones

Answer

Regulates glucose metabolism and insulin sensitivity

Answer

Inhibits osteoclast activity and decreases bone resorption

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?